Overview

BigHat Biosciences designs and develops antibody therapies by combining machine learning with synthetic biology. Its Milliner platform integrates a wet-lab workflow with AI to discover, engineer, and fully characterize hundreds of recombinant antibodies each week, enabling rapid development of safer and more effective treatments for hard-to-treat diseases such as certain infections and cancers. Unlike traditional antibody discovery, Milliner provides end-to-end screening, purification, and characterization in a high-throughput, weekly workflow, speeding up the path from concept to candidate. The company differentiates itself through its integrated platform that couples ML-driven design with synthetic biology experimentation, a focus on challenging diseases, and a culture that emphasizes work-life balance. Its goal is to deliver faster, safer antibody therapies to patients by expanding access to rapid discovery and engineering capabilities for healthcare providers and patients alike.